Hard to Treat Diseases (HTDS) Melem Secrets' Neutraceutical Products

OTTAWA, March 25 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) Further to the previously announced cosmetics merger (press release Feb 25, 2010) between Melem Secret's and Collagenna Skin Care Products, the company has decided to develop its neutraceutical business of supplements and natural health products under the Melem Secret brand.

Collagenna's CEO Michael Arnkvarn states: "We have been promoting a few supplements for optimal skin care but we have identified several other health products which we would like to bring to market. We feel that we need to create a brand independent of our skin care line. The Melem Secret brand will focus mainly on supplements and natural health products and Collagenna will continue its Skin Care brand."

New packaging is being developed along with a total revamp of the website www.melemsecret.com to reflect this new direction. Melem Secret has retained the services of a professional internet marketer in order to jump start the marketing efforts of the new brand. The new brand launch is expected to start in about 15-30 days and it will feature the introduction of Melem Secret's new Baobab supplement. This product originates from Africa and has mainly highly attractive health benefits: high antioxidant value, high source of calcium, rich in iron, potassium, magnesium and Vitamin C.

Other products that are ready to be marketed by Melem Secret include Marine Collagen Capsules, Omega 3 gel capsules as well as the Skin Defense Complex Caps.

The company reminds its shareholders and followers to monitor PinkSheets.com Filing section and also our IR company web site section "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/ for non newsworthy corporate updates.

For any matters relating to retail investor queries or to send the company or its IR a message please click on the "INVESTOR SUPPORT" TAB, or the direct link http://www.minamargroup.net/helpdesk.

Don't be a victim. Report a stock basher. The company is mindful that short sellers, the company competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas. Visit http://www.stockbasher.com/ and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and the remedies available to you as an individual investor.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe or opt in mailer at http://www.minamargroup.com/updates.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk

SOURCE Hard to Treat Diseases